닫기
검색

Scientific Advisory Board

Oncology
Sunil Sharma
Sunil SharmaMD, Ph.D.
Dr. Sharma is Deputy Director, Clinical Sciences; Professor and Division Director, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen); Chief, Translational Oncology Research & Drug Discovery; HonorHealth Research Institute. Previously he was the Jon and Karen Huntsman Presidential Professor for Cancer Research, Deputy Center Director, at the Huntsman Cancer Institute at the University of Utah. Dr. Sharma has conducted over 150 phase 1-2 oncology clinical trials as primary investigator over the past 15 years. Dr. Sharma was a VP at Novartis in charge of their early clinical oncology program, started the G/I oncology investigational program at the Nevada Cancer Institute in Las Vegas. Dr. Sharma has also worked at Sloan Kettering Memorial Hospital, one of the most prestigious cancer hospitals in the world.
Robert Maki
Robert MakiMD, Ph.D.
Dr. Maki is a professor of medicine at Weill-Cornell Medical School and full Member at Memorial Sloan-Kettering Cancer Center. He has worked for over 25 years in sarcoma medical oncology and experimental therapeutics, leading and/or programs in clinical cancer research for adult and pediatric patients in several institutions. He worked previously at the leader of sarcoma and phase 1 programs at Abramson Cancer Center University of Pennsylvania, leader in translational oncology at Northwell Health and Cold Spring Harbor Laboratory on Long Island, New York, and served as chief of Pediatric Hematology-Oncology at Mt Sinai Medical Center, New York. He holds a PhD in Immunology from MSKCC/Cornell as well.
Dong-Wan Kim
Dong-Wan KimMD, Ph.D.
Dr. Dong-Wan Kim is a Professor at the Seoul National University Hospital (SNUH), Seoul, Korea. Dr. Kim received his MD and PhD degree from the SNU and completed a residency in internal medicine at the SNUH. After completing his medical oncology and hematology fellowship at the SNUH, he has been working at the SNUH and the SNU College of Medicine as a staff member since 2003. Dr. Kim’s specialty is medical treatment for lung cancer and his research interests include clinical and translational research on thoracic malignancies. He has extensive experience in conducting clinical studies including first-in-human phase I studies with molecular targeted agents and immune-oncology trials. Also, he is the author of more than 200 academic papers in peer reviewed international journals.
Keun-Wook Lee
Keun-Wook LeeMD, Ph.D.
Dr. Keun-Wook Lee is a professor at Seoul National University College of Medicine (SNUCM) and Seoul National University Bundang Hospital (SNUBH), Korea. Dr. Lee earned MD and PhD degrees from SNUCM. He completed his residency in internal medicine and fellowship in medical oncology and hematology at Seoul National University Hospital (SNUH). Then, since 2005, he has been working at SNUCM and SNUBH. He is an expert in the chemotherapy for gastrointestinal cancers and has very rich cancer clinical trial experience including early phase clinical studies. He has authored more than 250 academic papers in peer-reviewed international journals. From 2020 to present, he is also the director of the Clinical Trial Center at SNUBH.
Ophthalmology
Patricia A D' Amore
Patricia A D' AmorePh.D., MBA
Pat is a professor of Ophthalmology at Harvard Medical School and Associate Chief of Basic & Translational Research at Massachusetts Eye and Ear. She is a world-renowned ocular angiogenesis expert who has made significant contributions in the identification of vascular endothelial growth factor(VEGF) as a primary ocular angiogenesis driver, leading to the approval of anti-VEGF therapies for treating retinal diseases. She also developed the oxygen-induced retinopathy(OIR) mouse model, which is widely used for preclinical studies of anti-angiogenic ocular therapeutics. She has published more than 160 papers and is the recipient of the Alcon Research Institute Award, the Cogan Award from ARVO, the Rous-Whipple Award from the American Society of Investigative Pathology, the Endre A. Balazs Award from the International Society for Eye Research, and the Proctor Medal from ARVO
Carl Regillo
Carl RegilloMD, FACS
Carl is Chief and Director of the Retina Service, Wills Eye Hospital in Philadelphia. He is the Principle Investigator of several major international clinical trials investigating new forms of treatment for a variety of retinal conditions including AMD and DR/DME. He is the Founder of Wills Eye Clinical Retina Research Unit and the former chairman of the Will Eye Institutional Review Board and the American Academy’s Basic and Clinical Science Course (BCSC) Retina Section committee. He has authored over 100 scientific papers, lectured nationally and abroad, and has published five major textbooks in the field. He has run several instructional courses at the annual American Academy of Ophthalmology meeting and is a recipient of the Academy's Achievement and Senior Achievement Awards in addition to the Secretariat Award.
Peter Kertes
Peter KertesMD, CM, FRCSC
Peter is Chief of Ophthalmology at the Sunnybrook Health Centre and an Associate Professor in the Department of Ophthalmology at the University of Toronto. He is a retinal surgeon with extensive experience in clinical trials for anti-angiogenic agents and is in search for better treatments for wet age-related macular degeneration(AMD) and diabetic retinopathy(DR). He specializes in the diagnosis and treatment of diseases of the retina, macula, and vitreous. With a burgeoning interest in international ophthalmology and pediatric retinal diseases such as Retinopathy of Prematurity(ROP), Peter seeks for opportunities volunteering his expertise.
Se Joon Woo
Se Joon WooMD, Ph.D.
Sejoon is an Associate Professor of Ophthalmology at Seoul National University Bundang Hospital(SNUBH). He is an active scientific researcher and ophthalmology medical doctor specializing in Pharmacokinetics(PK) study which is increasingly important for the successful development of anti-angiogenic therapies. He is also involved in multiple global clinical trials of novel retinal treatments and biosimilar agents, and has recently led the phase 3 global clinical trials of Lucentis biosimilar developed by Samsung Bioepis. He has published more than 230 peer-reviewed papers.